
non
US
Non-U.S./GlobalUS
Baron India Fund
Symbol BINDXCUSIP: 06828M595
Symbol BINDXCUSIP: 06828M595
Nav
$9.63
Daily Change $0.06 (0.63%)
As of 11/19/2026
As of 11/19/2026
Net Assets
$25.75 M
As of 09/30/2026
Inception date
07/30/2021
Prices & Performance
PricesAs of 11/19/2026
| NAV | Daily Change ($) | Daily Change (%) | MTD | QTD | YTD |
|---|---|---|---|---|---|
| $9.63 | $0.06 | 0.63% | 9.06% | 8.32% | 5.25% |
| NAV | $9.63 |
|---|---|
| Daily Change ($) | $0.06 |
| Daily Change (%) | 0.63% |
| MTD | 9.06% |
| QTD | 8.32% |
| YTD | 5.25% |
PerformanceAs of 09/30/2026
| Portfolio or Index | QTD1 | YTD1 | 1 Year | 3 Years | 5 Years | Since Inception 07/30/2021 |
|---|---|---|---|---|---|---|
| BINDX - Baron India Fund - I | -2.95% | -2.84% | -2.43% | 6.54% | -2.88% | -2.10% |
| MSCI AC Asia ex Japan/India Linked Index | -5.61% | -14.94% | -10.87% | -2.04% | -5.78% | -5.96% |
| MSCI India Index | -5.61% | -14.94% | -10.87% | 2.80% | 1.50% | 3.63% |
| MSCI Emerging Markets Index | -0.37% | 23.38% | 29.22% | 24.09% | 8.94% | 8.33% |
Performance InformationAs of 09/30/2026
| Performance statistics | 3 Years | Since Inception |
|---|---|---|
| Standard Deviation (%) | 16.25 | 17.20 |
| Sharpe Ratio | 0.11 | -0.34 |
| Alpha (%) | 8.43 | 3.19 |
| Beta | 0.88 | 0.86 |
| R-Squared (%) | 89.24 | 88.00 |
| Tracking Error (%) | 5.75 | 6.49 |
| Information Ratio | 1.49 | 0.60 |
| Upside Capture (%) | 107.27 | 96.72 |
| Downside Capture (%) | 72.01 | 82.98 |
Risk & Return12/31/2022 - 12/31/2025
Portfolio Holdings & Characteristics
HoldingsAs of 10/31/2026
| Holding | Sector | % of Net Assets | |
|---|---|---|---|
Divi's Laboratories Limited Divi's Laboratories Limited (DIVI.IN) is one of the world's leading pharmaceutical contract manufacturers and a global leader in several high-volume active pharmaceutical ingredients. Its custom synthesis business makes ingredients and intermediates for innovator drug companies. Divi's Laboratories Limited (DIVI.IN) has built strong relationships with global innovators and leading pharmaceutical companies and plays a key role in the global pharmaceutical value chain. In our view, it is a key beneficiary of global supply chain realignment, as its customers diversify their API sourcing away from China. We are encouraged that Divi’s has been onboarded by large global customers into the oral GLP-1 and GLP-1 injectables value chain as a supplier of complex intermediates and custom-manufactured peptides, which provides multi-year revenue visibility. | Health Care | 9.6% | |
Bajaj Finance Limited Bajaj Finance Limited (BAF.IN) is a leading non-banking financial company in India offering consumer durable financing, housing loans, small business credit, and other financial products. Its proprietary data analytics platform and large customer base support strong risk-adjusted returns. Bajaj Finance Limited (BAF.IN) is well positioned to benefit from growing demand for consumer financial services in India. The company’s data analytics platform is a key competitive advantage, enabling high risk-adjusted returns; in our view, return on equity can be sustained at 20% to 22%. Bajaj is also building a broader digital ecosystem, with apps offering insurance, brokerage, wealth management, and other financial products. We expect Bajaj to compound earnings at roughly 25% annually over the next five years. | Financials | 7.0% | |
ICICI Bank Limited ICICI Bank Limited (ICICIBC.IN) is India's second-largest private sector bank, with a strong capital base and an attractive deposit franchise. It focuses on retail banking, serving a largely underpenetrated market with a long runway for growth. ICICI Bank Limited (ICICIBC.IN) has improving profitability, supported by favorable trends in asset quality, margins, and costs. Management’s focus on improving the customer experience, expanding fintech partnerships, using data analytics to tailor products, and developing its mobile app into a broader digital platform should support market share gains and greater efficiency. We believe these initiatives could help narrow the valuation gap with other high-quality Indian private-sector banks. | Financials | 5.2% | |
Eternal Limited Eternal Limited (ZOMATO.IN), formerly Zomato, is one of the two dominant online food delivery platforms in India, also operating quick commerce, restaurant dining-out, and business-to-business supply businesses. It connects consumers, restaurants, and delivery partners through its technology platform. Eternal Limited (ZOMATO.IN) is well positioned to benefit from structural growth in online food delivery in India. The industry has become a duopoly between Swiggy and Eternal, which bodes well for future economics and scale. Eternal is also leading competition in the fast-growing quick commerce industry in India. We believe the company has the potential to double revenue while also improving profitability and growing earnings over the next three to five years. | Consumer Discretionary | 4.9% | |
HDFC Bank Limited HDFC Bank Limited (HDFCB.IN) is one of India's largest private sector banks, offering retail and commercial clients a broad range of financial services, including retail loans. Its extensive branch network and strong low-cost deposit franchise are key competitive advantages. HDFC Bank Limited (HDFCB.IN) is, in our view, a high-quality investment in Indian financials, supported by its record of consistent returns and strong management. Its leading deposit franchise and healthy asset quality provide a funding advantage, while continued investment in technology strengthens its digital banking capabilities. These advantages should support further market share gains and improved efficiency. | Financials | 4.5% | |
Acutaas Chemicals Limited Acutaas Chemicals Limited (ACUTAAS.IN) is an Indian manufacturer of advanced pharmaceutical intermediates and specialty chemicals, including battery electrolyte additives and semiconductor chemicals. Acutaas Chemicals Limited (ACUTAAS.IN) remains a company in which we have conviction as it scales its pharmaceutical contract development and manufacturing business through long-term agreements with Fermion to supply intermediates used in darolutamide, a fast-growing prostate cancer drug marketed by Bayer. Expansion into electrolyte additives and semiconductor chemicals should provide additional growth drivers. We believe Acutaas can compound revenue and earnings by more than 25% annually over the next three to five years. | Health Care | 4.3% | |
InterGlobe Aviation Limited InterGlobe Aviation Limited (INDIGO.IN) operates the IndiGo airline in India, providing scheduled passenger and cargo air transportation, along with ancillary travel services such as airport lounges and insurance. InterGlobe Aviation Limited (INDIGO.IN) has benefited from industry consolidation, while its scale and cost position help it navigate supply-chain constraints better than smaller competitors. We remain optimistic about rising air travel demand in India, potential for improved pricing discipline, and the company’s long-term international expansion. Its low-cost model and extensive network should support share gains and operating leverage. We expect EBITDAR to compound by 15% to 20% annually over the next three to five years. | Industrials | 4.1% | |
Precision Wires India Limited Precision Wires India Limited (PWI.IN) is a leading Indian manufacturer of copper winding wires, converting copper into enamelled wires and insulated conductors used in transformers, motors, and other electrical equipment, sold primarily to original equipment manufacturers. Precision Wires India Limited (PWI.IN) sells its products to original equipment manufacturers across a broad range of end markets, including automotive, aerospace and defense, power, electronics, home appliances, and infrastructure. The company benefits from long-standing customer relationships, scale advantages, and in-house R&D capabilities, which underpin its competitive positioning. Over the long term, we believe structural growth in India’s power sector and rising penetration of electric and hybrid vehicles should drive continued demand for Precision Wires’ products. | Industrials | 3.9% | |
Bharat Electronics Limited Bharat Electronics Limited (BHE.IN) is an Indian defense electronics company providing products and systems for military, government, and civilian customers, including radar, communication, electronic warfare, weapon systems, avionics, and electro-optics. Bharat Electronics Limited (BHE.IN) has sustained investment in in-house R&D and cost discipline that support a strong profitability profile. We believe the company is well positioned to benefit from India’s defense indigenization initiatives and rising defense spending. Expanding exports and non-defense businesses provide additional growth opportunities. We expect BEL to compound earnings by 15% to 20% annually over the next three to five years. | Industrials | 3.9% | |
Bharti Airtel Limited Bharti Airtel Limited (BHARTI.IN) is a leading telecommunications company, with operations in 18 countries across Asia and Africa. The company's offerings include wireless, mobile commerce, and fixed line. Bharti Airtel is a top-three player in the Indian telecommunications industry. With more than 30% market share, it is well positioned to benefit from rising smartphone penetration and 4G services in India. The company should continue to gain market share from Vodafone India, which is on the brink of bankruptcy and will likely need to raise mobile tariffs by more than 50% to remain a viable entity. We expect earnings to generate mid-teens growth over the next three to five years, with further upside from its broadband and enterprise businesses. | Communication Services | 3.4% | |
Total | 50.6% |
Top Ten Fund Holdings based on net assets. Portfolio holdings may change over time.
Portfolio holdings are subject to change. Current and future portfolio holdings are subject to risk.
Portfolio holdings are subject to change. Current and future portfolio holdings are subject to risk.
Contributors / DetractorsQuarterly as of 09/30/2026
| Top Contributors | Average Weight | Contribution |
|---|---|---|
| Divi's Laboratories Limited | 6.34% | 1.52% |
| Precision Wires India Limited | 5.93% | 1.07% |
| Centum Electronics Limited | 3.32% | 0.65% |
| Eternal Limited | 3.89% | 0.54% |
| KSH International Limited | 1.18% | 0.11% |
Source: FactSet PA.
GICS Sector BreakdownAs of 10/31/2026
Sector
Financials
25.8%
Industrials
23.8%
Health Care
19.9%
Consumer Discretionary
12.4%
Information Technology
7.8%
Utilities
3.9%
Communication Services
3.4%
Materials
2.5%
Consumer Staples
1.6%
Diversified Banks10.6%
Life Sciences Tools & Services9.6%
Consumer Finance9.4%
Pharmaceuticals8.0%
Aerospace & Defense7.0%
Industrial Machinery & Supplies & Components 6.6%
Restaurants4.9%
Electrical Components & Equipment4.6%
Passenger Airlines 4.1%
Wireless Telecommunication Services3.4%
Electronic Components3.3%
Investment Banking & Brokerage3.0%
Communications Equipment2.6%
Asset Management & Custody Banks2.6%
Health Care Facilities2.3%
024681012
Diversified Banks10.6%
Life Sciences Tools & Services9.6%
Consumer Finance9.4%
Pharmaceuticals8.0%
Aerospace & Defense7.0%
Industrial Machinery & Supplies & Components 6.6%
Restaurants4.9%
Electrical Components & Equipment4.6%
Passenger Airlines 4.1%
Wireless Telecommunication Services3.4%
Electronic Components3.3%
Investment Banking & Brokerage3.0%
Communications Equipment2.6%
Asset Management & Custody Banks2.6%
Health Care Facilities2.3%
024681012
India101.0%
01734516885102
India101.0%
01734516885102
Portfolio CharacteristicsAs of 09/30/2026
| Description | Baron India Fund | MSCI AC Asia ex Japan/India Linked Index |
|---|---|---|
| Inception Date | July 30, 2021 | |
| Net Assets | $25.75 million | |
| # of Issuers / % of Net Assets | 40/101.7% | |
| Turnover (1 Year Average) | ||
| Active Share | 77.8% | |
| Median Market Cap | $10.49 billion | $11.88 billion |
| Weighted Average Market Cap | $25.62 billion | $46.69 billion |
| Gross Expense Ratio | 2.30% | |
| Net Expense Ratio | 1.20% | |
| As of FYE Current Expense Ratio Date | 04/30/2026 | |
| EPS Growth (3-5 year forecast) | 18.9% | 14.3% |
| Price/Earnings Ratio (trailing 12-month) | 40.0x | 19.5x |
| Price/Book Ratio | 6.6x | 3.0x |
| Price/Sales Ratio | 4.5x | 2.2x |
The Net Assets include all share classes combined.
Valuation metrics were calculated using a weighted harmonic average. Source: FactSet PA. Internal projections may differ.
Valuation metrics were calculated using a weighted harmonic average. Source: FactSet PA. Internal projections may differ.
Distributions
| Record Date | Ex Date | Payable Date | Income | Return of Capital | Short-Term Capital Gain | Long-Term Capital Gain | Total | Re-Invest NAV | Calendar-Year Return |
|---|---|---|---|---|---|---|---|---|---|
| 12/15/2025 | 12/16/2025 | 12/17/2025 | $0.0481 | $0.0000 | $0.0000 | $0.0000 | $0.0481 | $9.00 | -0.34% |
| 09/23/2024 | 09/24/2024 | 09/25/2024 | $0.0268 | $0.0000 | $0.0000 | $0.0000 | $0.0268 | $9.95 | 17.75% |
For estimated distributions, visit the Tax Center